A Phase I Open label, Dose Finding Study of IMCgp100 in Patients with Advanced Malignant Melanoma
Diseases and Conditions Researched
What is the purpose of this trial?
This is a Phase 1, open-label, dose–finding study to assess the safety and tolerability of IMCgp100, a Monoclonal T Cell Receptor anti-CD3 scFv Fusion Protein, in patients with advanced malignant melanoma. Eligible patients will have Stage IV disease or unresectable Stage III disease.
Click here for detailed participation information for this trial.
How will my information be used?
When you express interest in a specific study, the information from your profile will be sent to the doctor conducting that study. If you're eligible to participate, you may be contacted by a nurse or study coordinator.
If you select a health category rather than a specific study, doctors who have active studies in that area may contact you to ask if you would like to participate.
In both cases, you will be contacted by the preferred method (email or phone) that you specified in your profile.